Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AASI-NSCLC: Adjuvant Atezolizumab in Stage I NSCLC
NCT07388524Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2027
- Primary completion
- Sep 2032
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Planned start Mar 2027; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07388524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388524.